Cardiff Oncology Inc reports results for the quarter ended in September - Earnings Summary

Cardiff Oncology

03/11/2022 20:33

* Cardiff Oncology Inc  CRDF.OQ  reported a quarterly
adjusted
loss of 20 cents​​ per share for the quarter ended in September.
The mean expectation of five analysts for the quarter was for a
loss of 26 cents per share.
    * Revenue rose 8.1% to $93.00 thousand from a year ago;
analysts
expected $68.20 thousand. 
    * Cardiff Oncology Inc's reported EPS for the quarter was a
loss
of 20 cents​.
    * The mean earnings estimate of analysts had risen by
about 4.3%
in the last three months.​ 
    * In the last 30 days there have been no earnings estimate
revisions by analysts covering the company. 
    * Cardiff Oncology Inc shares had fallen by 3.2% this
quarter and
lost 75.2% so far this year.
    * The company reported a quarterly loss of $8.58 million.
    * Wall Street's median 12-month price target for Cardiff
Oncology
Inc is $5.00 
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 5 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 

This summary was machine generated from Refinitiv data November
3 at 08:33 p.m.  ​All figures in US dollars unless otherwise
stated. QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Sep. 30 2022      -0.26          -0.20          Beat
 Jun. 30 2022      -0.25          -0.24          Beat
 Mar. 31 2022      -0.23          -0.25          Missed
 Dec. 31 2021      -0.17          -0.23          Missed